TransThera Sciences (Nanjing), Inc.
藥捷安康(南京)科技股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2617)

VOLUNTARY ANNOUNCEMENT
INTENTION TO CONDUCT ON-MARKET SHARE REPURCHASE UNDER GENERAL MANDATE

This announcement is made by the board of directors (the "**Board**") of TransThera Sciences (Nanjing), Inc. (the "**Company**", together with its subsidiaries, the "**Group**") on a voluntary basis.

The Board hereby announces that the Company intends to repurchase H shares of the Company (the "**H Shares**") in the open market from time to time up to an aggregate amount of RMB100 million or its equivalent in Hong Kong dollars (the "**Share Repurchase**") pursuant to the general mandate to repurchase H Shares as approved by the shareholders of the Company (the "**Shareholders**") at the annual general meeting (the "**AGM**") of the Company held on 18 June 2026 (the "**Repurchase Mandate**"). The Share Repurchase will be funded by funds permitted under applicable laws and regulations. The period for the Share Repurchase shall commence from the date of passing of the resolution at the aforementioned AGM and expire at the earliest of: (1) the conclusion of the next AGM of the Company; (2) the expiration of the period within which the Company is required to hold the next AGM by the articles of association of the Company or any applicable laws; and (3) the date on which Shareholders revoke or amend the mandate set out in the resolution of the aforementioned AGM by way of a special resolution in a general meeting.

The Company will conduct the Share Repurchase in compliance with the articles of association of the Company, the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited, the Codes on Takeovers and Mergers and Share Buy-backs, the laws of the People's Republic of China and all other applicable laws and regulations to which the Company is subject, and upon approval from the relevant regulatory authorities (if necessary). The Company will subsequently cancel, hold in treasury, sell or transfer the repurchased H Shares, if any, as deemed appropriate by the Board.

The Board believes that conducting the Share Repurchase in the present conditions will demonstrate the Company's confidence in its own business outlook and prospects and would, ultimately, benefit the Company and the Shareholders. The Board also believes that the current financial resources of the Company would enable it to implement the Share Repurchase while maintaining a solid financial position.

Shareholders and potential investors should note that, as of the date of this announcement, the Company has not repurchased any H Shares. Any Share Repurchase will be done subject to market conditions and at the Board's absolute discretion. There is no assurance of the timing, quantity or price of any repurchase of H Shares. Shareholders and potential investors should therefore exercise caution when dealing in the securities of the Company.

By order of the Board
TransThera Sciences (Nanjing), Inc.
藥捷安康(南京)科技股份有限公司
Dr. Frank Wu
Chairman and Chief Executive Officer

Hong Kong, 28 June 2026

As at the date of this announcement, the Board comprises Dr. Frank Wu and Mr. Wu Di as executive Directors; Ms. Jia Zhongxin as a non-executive Director; and Mr. Li Shu Pai, Ms. Chui Hoi Yam and Mr. Feng Weibo as independent non-executive Directors.